Allogeneic Regulatory T cells (Tregs)

Within the CytoSage Team there are many decades of clinical cell therapy development experience. This expertise extends through conduct of phase 1 to 3 clinical trials in anti-inflammatory cell therapy in CNS trauma and stroke and secondary consequences of trauma, such as acute respiratory distress syndrome (ARDS). CytoSage will be developing a novel clinical Treg cell therapy candidate, for treatment of the at-risk trauma patient population. CytoSage have access to both cGMP facilities for clinical cell therapy development, incorporating a continued source of thymic regulatory T cells (Tregs) for generation of an allogeneic anti-inflammatory cell therapy. 

In targeting therapy, CytoSage also looks to address the unmet medical need of identifying patients in the acute injury/trauma space at risk for secondary pathology of ARDS, acute kidney disease and coagulopathy by developing novel proprietary algorithms derived from multivariate analysis of associated blood biomarker levels.

Proprietary Technology

CytoSage has in-licensed novel, proprietary, multiplex proteomic assay technology, to refine and optimize current novel algorithms for identifying post-trauma/acute injury patients at risk for progressing into immune dysfunction-related secondary pathophysiology. The ability to identify at risk patients earlier in the treatment process would be a fundamental step forward in trauma medicine.

Immunomodulation and Anti-inflammatory Potency Monitoring

Through their prior experience in anti-inflammatory cell therapy development and human immune cell pharmacology, CytoSage’s cell therapy development already incorporates the necessary expertise to establish anti-inflammatory potency monitoring across multiple immune cell types for regulatory purposes.

Direction

Through this approach, the company is looking to be the leader in both identification and treatment of trauma-related pathophysiology.